CLEVELAND (WJW) — The U.S. Food and Drug Administration Monday approved a new first-of-its-kind treatment for adults living with Parkinson’s disease.
Cleveland Clinic Lerner College of Medicine professor Hubert Fernandez served as the global lead clinical investigator for the treatment.
“Now we have a novel therapy that selectively targets D1/D5 receptors, which addresses a longstanding need for innovation and provides health care providers with greater flexibility to tailor treatment to individual patient needs,” Fernandez said in a press release…